TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of Hodgkin and non-Hodgkin lymphomas.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with Hodgkin and non-Hodgkin lymphomas.

LEARNING OBJECTIVES

• Evaluate how patient- and disease-specific factors affect the selection and sequencing of therapies for follicular lymphoma, and counsel patients regarding personalized treatment recommendations.
• Recognize the mechanisms of action of and available and emerging data with novel therapies approved for the treatment of diffuse large B-cell lymphoma, and thus determine the current and potential utility of these agents in clinical practice.
• Develop an understanding of published clinical research findings guiding the management of newly diagnosed and relapsed/refractory (R/R) mantle cell lymphoma, and use this information in patient education discussions.
• Review available efficacy and safety data with chimeric antigen receptor T-cell therapies directed at CD19, and identify patients with non-Hodgkin lymphoma for whom this approach may be appropriate as part of or outside a clinical research study.
• Assess recent therapeutic advances for patients with newly diagnosed and R/R Hodgkin lymphoma, and use this information to enhance treatment decision-making.
• Educate patients about the side effects associated with approved therapies commonly used in the management of various forms of lymphoma, and provide preventive strategies to reduce or ameliorate these toxicities.
• Recall the design of ongoing clinical trials evaluating novel investigational strategies for the treatment of Hodgkin and non-Hodgkin lymphomas, and counsel appropriately selected patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
NCPD credit is no longer available for this issue

ONCC/ILNA CERTIFICATION INFORMATION
NCPD credit is no longer available for this issue

FOR SUCCESSFUL COMPLETION
Audio Program: This NCPD activity consists of an audio component.
NCPD credit is no longer available for this issue

Video Program: This NCPD activity consists of a video component.
NCPD credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Christopher R Flowers, MD, MS
Chair, Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Curio Science, Denovo Biopharma, Epizyme Inc, Foresight Diagnostics, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Janssen Biotech Inc, MEI Pharma Inc, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Seagen Inc; Research Funding: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Celgene Corporation, Cellectis, Eastern Cooperative Oncology Group, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, National Cancer Institute, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, The V Foundation for Cancer Research, Xencor, ZIOPHARM Oncology Inc.

Robin Klebig, APRN, CNP, AOCNP 

Nurse Practitioner
Assistant Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

No relevant conflicts of interest to disclose.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from ADC Therapeutics, Incyte Corporation, and Seagen Inc.

Release date: July 2022
Expiration date: July 2023

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.